Register Login

Kymera Therapeutics Inc (KYMR)

(90% Positive) Kymera Therapeutics Inc (KYMR) Announces Enrollment Update for medicines Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:29 p.m.

    📋 Kymera Therapeutics Inc (KYMR) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 07:08:20

    Event Type: Clinical Trial Update

    Event Details:

    Kymera Therapeutics Inc (KYMR) Announces Clinical Trial Update Kymera Therapeutics Inc (KYMR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: medicines, program
    • Diseases/Conditions: immunological diseases, asthma initiated
    • Clinical Stage: Phase 1, clinical trial
    • Collaboration: Kymera Therapeutics, Inc.
      • expected by mid-2027
      • expected in late-2027
      • expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026

    🔬 Clinical Development Pipeline (Kymera Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    Placebo OTHER Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    KT-621 DRUG Phase PHASE1 Atopic Dermatitis ClinicalTrials.gov
    KT-474 DRUG Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    KT-474/Placebo DRUG Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    KT-253 DRUG Phase PHASE1 Myeloid Malignancies ClinicalTrials.gov
    KT-413 DRUG Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    KT-333 DRUG Phase PHASE1 Non Hodgkin Lymphoma (NHL) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Kymera Therapeutics Inc
    • Ticker Symbol: KYMR

Search

News categories